Investing.com -- U.S. futures rose Wednesday, rebounding after three days
Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.” | Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.”
The latest immunization triggered a stronger immune response against some COVID strains in the phase 3 pivotal trial, notably in participants over age 65, the Cambridge-based drug company said.
Biotech firm Moderna has good news for humanity. The company is preparing for its post-Covid vaccine, which will be more effective than the previous jabs.
Moderna announced positive clinical trial data on three experimental